AMGN06.BK Amgen Inc.

- THB
Market cap
-
P/E
-
P/B
-
ROE
-
Dividend yield
1.22%
Fundamental score
-

Is AMGN06.BK undervalued?

Graham number

The Graham number of Amgen Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Amgen Inc. fundamental analysis

No fundamental analysis for Amgen Inc. yet.

Amgen Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Amgen Inc.

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which re…

Full company profile